Bibliographies thématiques / Singola molecola / Articles de revues
Pour voir les autres types de publications sur ce sujet consultez le lien suivant : Singola molecola.

Articles de revues sur le sujet « Singola molecola »

Auteur : Grafiati
Publié le 9 mars 2023
Mis à jour le 19 juillet 2025

Créez une référence correcte selon les styles APA, MLA, Chicago, Harvard et plusieurs autres

Choisissez une source :

Consultez les 50 meilleurs articles de revues pour votre recherche sur le sujet « Singola molecola ».

À côté de chaque source dans la liste de références il y a un bouton « Ajouter à la bibliographie ». Cliquez sur ce bouton, et nous générerons automatiquement la référence bibliographique pour la source choisie selon votre style de citation préféré : APA, MLA, Harvard, Vancouver, Chicago, etc.

Vous pouvez aussi télécharger le texte intégral de la publication scolaire au format pdf et consulter son résumé en ligne lorsque ces informations sont inclues dans les métadonnées.

Parcourez les articles de revues sur diverses disciplines et organisez correctement votre bibliographie.

1

Pancani, Roberta, Alessandra Pagano, Marta Lomi, Elisabetta Casto, Sara Cappelli, and Alessandro Celi. "Farmaci antitumorali e tromboembolismo venoso." Cardiologia Ambulatoriale 31, no. 2 (2023): 139–48. http://dx.doi.org/10.17473/1971-6818-2023-2-6.

Texte intégral
Résumé :
Studi di popolazione hanno evidenziato un incremento dell’incidenza di tromboembolismo venoso (TEV) nei pazienti neoplastici in corso di trattamento con farmaci antitumorali. Sono state condotte ricerche cliniche allo scopo di chiarire il possibile ruolo di singoli agenti antitumorali nella modulazione del rischio di TEV, riscontrando fra essi alcune differenze. Gli studi disponibili presentano diversi limiti: non consentono un confronto diretto tra molecole poiché gli schemi di trattamento si basano generalmente su combinazioni di farmaci e spesso per ricavare dati su una singola molecola è necessario estendere lo studio a tumori di tipologie, sedi o comportamento biologico differenti; inoltre è probabile che alle differenze riscontrate contribuisca un rischio di TEV già di per sé aumentato nei pazienti in fase avanzata di malattia. Una possibile strategia per limitare l’incidenza di TEV potrebbe essere quella di sottoporre i pazienti oncologici in trattamento antitumorale a profilassi antitrombotica primaria. Per tale profilassi non esiste attualmente una raccomandazione solida, in virtù di dati contrastanti, sia sulle terapie con eparine frazionate che con farmaci anticoagulanti orali diretti (DOAC), sul rapporto fra il beneficio in termini di prevenzione degli eventi tromboembolici sintomatici ed il rischio di sanguinamenti maggiori o clinicamente rilevanti. L’introduzione in commercio di inibitori del fattore XIa, dei quali sono in corso studi di fase 2, potrebbe modificare lo scenario attuale. Un problema che sta acquisendo rilevanza sempre maggiore è quello delle possibili interazioni farmacologiche fra i farmaci anticoagulanti orali e i farmaci antitumorali. In questo senso, l’utilizzo dei DOAC può essere vantaggioso rispetto a quello degli inibitori della vitamina K, nonostante una potenziale maggiore difficoltà nel controllo delle interazioni, qualora presenti, dovuta al fatto che il dosaggio plasmatico dei DOAC non viene normalmente sottoposta a monitoraggio. Le interazioni fra i DOAC e i farmaci antitumorali sono state ipotizzate sulla base dell’azione su molecole coinvolte nella farmacodinamica di entrambe le categorie di farmaci, quali la glicoproteina-p (P-gp) o il citocromo CYP3A4; pur non essendo mai state studiate in vivo, è necessario prendere in considerazione la possibilità di tali interazioni nella pratica clinica. Alcune opportunità per affrontare il problema sono rappresentate dal dosaggio plasmatico dei DOAC e dalla somministrazione dei due farmaci in momenti il più possibile lontani nella giornata.
Styles APA, Harvard, Vancouver, ISO, etc.
2

Marcucci, Guido, Drew Watson, Shweta Kapoor, et al. "Superior therapy response predictions for patients with acute myeloid leukemia (AML) using Cellworks Singula: MyCare-009-01." Journal of Clinical Oncology 38, no. 15_suppl (2020): e19502-e19502. http://dx.doi.org/10.1200/jco.2020.38.15_suppl.e19502.

Texte intégral
Résumé :
e19502 Background: Despite using cytogenetic and molecular-risk stratification and precision medicine, the current overall outcome of AML patients remains relatively poor. Therapy selection is often based on information considering only cytogenetics and single molecular aberrations and ignoring other patient-specific omics data that could potentially enable more effective treatments. The Cellworks Singula™ report predicts response for physician prescribed therapies (PPT) using the novel Cellworks Omics Biology Model (CBM) to simulate downstream molecular effects of cell signaling, drugs, and radiation on patient-specific in silico diseased cells. We test the hypothesis that Singula is a more accurate predictor of patient-specific therapy response than PPT. Methods: Singula’s ability to predict response was evaluated in an independent, randomly selected, retrospective cohort of 494 AML patients aged 2 to 85 years (median 54) treated with PPT. Patient omics data was available from PubMed. The accuracy of Singula was compared to that of PPT using McNemar’s test to account for the correlation between Singula and PPT. Multivariate logistic regression modeled complete response (CR) as a function of patient age, PPT, and Singula against any non-response (NR). Likelihood ratio tests were performed to further validate if Singula provides predictive information beyond PPT or patient age. Similar analyses were performed for overall survival (OS) using proportional hazards regression. Results: Singula was a better predictor for CR than PPT (McNemar’s χ2 = 72.0, p-value < 0.0001), with an overall accuracy of 88.5% (95% CI: 85.3%, 91.1%) compared to 70.2% (95% CI: 66.0%, 74.2%) for PPT. Singula exhibited a sensitivity and specificity of 97.1% and 68.0%, respectively. In multivariate regression analysis, Singula (p < 0.0001) remained an independent predictor for CR after adjusting for patient age (p = 0.0329) while PPT became not significant (p = 0.75). Singula was also an independent predictor for OS (p < 0.0001) after adjusting for patient age (p = 0.0018) and PPT (p = 0.0011). For all 100 true negatives, Singula generated alternative standard of care therapy selections with predicted clinical response. Conclusions: Singula is a superior independent predictor for CR and OS compared to PPT in AML patients. The Singula report can also validate therapy selection, correctly identify non-responders to PPT and further provide alternative therapy selections.
Styles APA, Harvard, Vancouver, ISO, etc.
3

Stein, Anthony Selwyn, Drew Watson, Shweta Kapoor, et al. "Superior therapy response predictions for patients with myelodysplastic syndrome (MDS) using Cellworks Singula: MyCare-009-02." Journal of Clinical Oncology 38, no. 15_suppl (2020): e19528-e19528. http://dx.doi.org/10.1200/jco.2020.38.15_suppl.e19528.

Texte intégral
Résumé :
e19528 Background: Despite using cytogenetic and molecular-risk stratification and precision medicine, the current overall outcome of MDS patients remains relatively poor. Therapy selection is often based on information considering only cytogenetics and single molecular aberrations and ignoring other patient-specific omics data that could potentially enable more effective treatments. The Cellworks Singula™ report predicts response for physician prescribed therapies (PPT) using the novel Cellworks Omics Biology Model (CBM) to simulate downstream molecular effects of cell signaling, drugs, and radiation on patient-specific in silico diseased cells. We test the hypothesis that Singula is a more accurate predictor of patient-specific therapy response than PPT. Methods: Singula’s ability to predict response was evaluated in an independent, randomly selected, retrospective cohort of 146 MDS patients aged 28 to 89 years (median 69) treated with PPT. Patient omics data was available from PubMed and TCGA. The accuracy of Singula was compared to that of PPT using McNemar’s test to account for the correlation between Singula and PPT. Multivariate logistic regression modeled complete response (CR) as a function of patient age, PPT, and Singula against any non-response (NR). Likelihood ratio tests were performed to further validate if Singula provides predictive information beyond PPT or patient age. Similar analyses were performed for overall survival (OS) using proportional hazards regression. Results: Singula was a better predictor for CR than PPT (McNemar’s χ2 = 42.0, p-value < 0.0001), with an overall accuracy of 73.3% (Exact 95% CI: 65.3%, 80.2%) compared to 37.7% (95% CI: 30.0%, 46.1%) for PPT. Singula exhibited a sensitivity and specificity of 90.9% (95% CI: 80.0%, 97.0%) and 62.6% (95% CI: 51.8%, 72.6%), respectively. In multivariate regression analysis, Singula (p < 0.0001) remained an independent predictor for CR after adjusting for patient age (p = 0.0759) and PPT (p = 0.0496). Singula provided alternative therapy selections for 17 of 53 true negative detected by Cellworks. Conclusions: Singula is a superior independent predictor for CR compared to PPT in MDS patients. The Singula report can also validate therapy selection, correctly identify non-responders to PPT and further provide alternative therapy selections.
Styles APA, Harvard, Vancouver, ISO, etc.
4

Wen, Patrick Y., Drew Watson, Shweta Kapoor, et al. "Superior therapy response predictions for patients with glioblastoma (GBM) using Cellworks Singula: MyCare-009-03." Journal of Clinical Oncology 38, no. 15_suppl (2020): 2519. http://dx.doi.org/10.1200/jco.2020.38.15_suppl.2519.

Texte intégral
Résumé :
2519 Background: Despite using cytogenetic and molecular-risk stratification and precision medicine, the current overall outcome of GBM patients remains relatively poor. Therapy selection is often based on information considering only a single aberration and ignoring other patient-specific omics data which could potentially enable more effective treatment selection. The Cellworks Singula™ report predicts response for physician prescribed therapies (PPT) using the novel Cellworks Omics Biology Model (CBM) to simulate downstream molecular effects of cell signaling, drugs, and radiation on patient-specific in silico diseased cells. We test the hypothesis that Singula is a superior predictor of progression-free survival (PFS) and overall survival (OS) compared to PPT. Methods: Singula’s ability to predict response was evaluated in an independent, randomly selected, retrospective cohort of 109 GBM patients aged 17 to 83 years treated with PPT. Patient omics data was available from TCGA. Singula uses PubMed to generate protein interaction network activated and inactivated disease pathways. We simulated PPT for each patient and calculated the quantitative drug effect on a composite GBM disease inhibition score based on specific phenotypes while blinded to clinical response. Univariate and multivariate proportional hazards (PH) regression analyses were performed to determine if Singula provides predictive information for PFS and OS, respectively, above and beyond age and PPT. Results: In univariate analyses, Singula was a significant predictor of both PFS (HR = 4.130, p < 0.000) and OS (HR = 2.418, p < 0.0001). In multivariate PH regression analyses, Singula (HR = 4.033, p < 0.0001) remained an independent predictor of PFS after adjustment for PPT (p = 0.1453) and patient age (p = 0.4273). Singula (HR = 1.852, p = 0.0070) was also a significant independent predictor of OS after adjustment for PPT (p = 0.4127) and patient age (p = 0.0003). Results indicate that Singula is a superior predictor of both PFS and OS compared to PPT. Singula provided alternative therapy selections for 29 of 52 disease progressors detected by Cellworks. Conclusions: Singula is a superior predictor of PFS and OS in GBM patients compared to PPT. Singula can identify non-responders to PPT and provide alternative therapy selections.
Styles APA, Harvard, Vancouver, ISO, etc.
5

Ahluwalia, Manmeet Singh, Drew Watson, Shweta Kapoor, et al. "Superior therapy response predictions for patients with low-grade glioma (LGG) using Cellworks Singula: MyCare-009-04." Journal of Clinical Oncology 38, no. 15_suppl (2020): 2569. http://dx.doi.org/10.1200/jco.2020.38.15_suppl.2569.

Texte intégral
Résumé :
2569 Background: Despite using cytogenetic and molecular-risk stratification and precision medicine, the current overall outcome of LGG patients remains relatively poor. Therapy selection is often based on information considering only a single aberration and ignoring other patient-specific omics data which could potentially enable more effective treatments. The Cellworks Singula report predicts response for physician prescribed therapies (PPT) using the novel Cellworks Omics Biology Model (CBM) to simulate downstream molecular effects of cell signaling, drugs, and radiation on patient-specific in silico diseased cells. We test the hypothesis that Singula is a superior predictor of progression-free survival (PFS) and overall survival (OS) compared to PPT. Methods: Singula’s ability to predict response was evaluated in an independent, randomly selected, retrospective cohort of 137 LGG patients aged 14 to 73 years treated with PPT. Patient omics data was available from TCGA. Singula uses PubMed to generate protein interaction network activated and inactivated disease pathways. We simulated the PPT for each patient and calculated the quantitative drug effect on a composite LGG disease inhibition score based on specific phenotypes while blinded to clinical response. Univariate and multivariate proportional hazards (PH) regression analyses were performed to determine if Singula provides predictive information for PFS and OS, respectively, above and beyond age and PPT. Results: In univariate analyses, Singula was a significant predictor of both PFS (HR = 3.587, p < 0.0001) and OS (HR = 3.044, p = 0.0007). In multivariate PH regression analyses, Singula (HR = 3.707, p < 0.0001) remained an independent predictor of PFS after adjustment for PPT (p = 0.3821) and patient age (p = 0.0020). Singula (HR = 2.970, p = 0.0013) was also a significant independent predictor of OS after adjustment for PPT (p = 0.0540) and patient age (p < 0.0001). Results indicate that Singula is a superior predictor of both PFS and OS compared to PPT. Singula provided alternative standard of care therapy selections for all 34 disease progressors. Conclusions: Singula is a superior predictor of PFS and OS in LGG patients compared to PPT. Singula can correctly identify non-responders to PPT and provide alternative therapy selections.
Styles APA, Harvard, Vancouver, ISO, etc.
6

Marcucci, Guido, Drew Watson, Prashant Ramachandran Nair, et al. "Assessment of Cellworks Omics Biosimulation Therapy Response Predictions for Patients with Acute Myeloid Leukemia (AML) Using Cellworks Singula™: Mycare-020-01." Blood 136, Supplement 1 (2020): 35. http://dx.doi.org/10.1182/blood-2020-142184.

Texte intégral
Résumé :
Background. In addition to clinical considerations (e.g., age, de novo vs secondary disease, comorbidities), therapy selection for AML patients is often based on information considering only cytogenetics and/or molecular aberrations and ignoring other patient-specific omics information that could potentially enable selection of more effective treatments. In turn, despite using cytogenetic and molecular-risk stratification, the current overall outcome of AML patients remains relatively poor. The Cellworks Singula™ report predicts clinical response to physician-prescribed treatments using the novel Cellworks Omics Biology Model (CBM) that simulate in silico downstream molecular effects on cell signaling and survival of drug treatments in patient-specific diseased cells. Methods. The performance of Singula™ was evaluated in a cohort of 474 AML patients aged 2 to 85. The pre-defined Singula™ Classifier utilizes individual patients' next-generation sequencing (NGS) profiles to provide a dichotomous prediction of response or non-response to the physician prescribed treatments. The clinical outcome data for these subjects, i.e., complete response (CR) and overall survival (OS), were obtained from the TCGA and other 144 PubMed publications, each including also information on patients' cytogenetics, targeted gene mutations, and/or whole exome sequencing. Blinded to clinical outcomes, Cellworks utilized the cytogenetic and molecular data to generate a Singula™ predicted response (i.e., CR vs non-response) classification for each patient. Statistical analyses, including assessments of accuracy, sensitivity, specificity, and negative (NPV) and positive predictive (PPV) values were performed to compare the Singula™ predicted clinical response to the actual observed clinical response. Kaplan-Meier curves, associated log rank tests and median OS are provided for patients stratified by Singula™ predicted response. Multivariate Cox proportional hazards regression was used to further test the hypothesis that Singula™ is an independent predictor for OS once adjusted for patient age and actual prescribed treatment. Results. Data are summarized in Table 1. The Singula™ classifier had 92.3% (90.6%, 95.3%) accuracy in predicting correctly observed patient complete response to the prescribed treatment. with 97.3% (95.0%, 98.8%) sensitivity. Singula™ had 83.3% (76.1%, 89.1%) specificity for the non-responder patients (n=138; 29.1%). For each of the non-responders, Singula™ provided an alternative treatment therapy predicted to produce clinical response. Assuming at least 2% of the non-responders would have responded to the alternative Singula™ prescribed treatment, Singula™ improves CR rates compared to the original physician prescribed treatment (McNemar's p-value < 0.05). Figure 1 provides the Kaplan-Meier curves of Singula-predicted responders vs non-responders for a subset of 292 subjects that had OS data available. In multivariate Cox proportional hazards models, the Singula Classifier remained a significant predictor of overall survival (HR = 2.171, p-value < 0.0001) once adjusted for patient age and physician prescribed treatment. Conclusions. Cellworks Singula™ has high accuracy and sensitivity in predicting CR for AML patient. Singula also has high specificity in identifying patients who are unlikely to respond physician and may prescribed potentially effective therapies. The Singula™ predicted responders have a significantly longer OS than the predicted non responders. Thus, Cellworks Singula™ can accurately predict AML response, be used to validate or reject a physician's therapy selection decision and, eventually, provide alternative treatment recommendations. Disclosures Marcucci: Novartis: Speakers Bureau; Abbvie: Speakers Bureau; Iaso Bio: Membership on an entity's Board of Directors or advisory committees; Takeda: Other: Research Support (Investigation Initiated Clinical Trial); Pfizer: Other: Research Support (Investigation Initiated Clinical Trial); Merck: Other: Research Support (Investigation Initiated Clinical Trial). Watson:Mercy Bioanalytics, Inc.: Consultancy, Membership on an entity's Board of Directors or advisory committees; SEER Biosciences, Inc.: Consultancy, Membership on an entity's Board of Directors or advisory committees; BioAI Health Inc.: Consultancy, Membership on an entity's Board of Directors or advisory committees; Cellmax Life Inc.: Consultancy, Membership on an entity's Board of Directors or advisory committees; Cellworks Group Inc.: Consultancy, Membership on an entity's Board of Directors or advisory committees. Nair:Cellworks Research India Private Limited: Current Employment. Basu:Cellworks Research India Private Limited: Current Employment. Ullal:Cellworks Research India Private Limited: Current Employment. Ghosh:Cellworks Research India Private Limited: Current Employment. Narvekar:Cellworks Research India Private Limited: Current Employment. Grover:Cellworks Research India Private Limited: Current Employment. Sahu:Cellworks Research India Private Limited: Current Employment. Amara:Cellworks Research India Private Limited: Current Employment. Pampana:Cellworks Research India Private Limited: Current Employment. Roy:Cellworks Research India Private Limited: Current Employment. Rajagopalan:Cellworks Research India Private Limited: Current Employment. Alam:Cellworks Research India Private Limited: Current Employment. Parashar:Cellworks Research India Private Limited: Current Employment. Mundkur:Cellworks Group Inc.: Current Employment. Christie:Cellworks Group Inc.: Current Employment. Macpherson:Cellworks Group Inc.: Current Employment. Kapoor:Cellworks Research India Private Limited: Current Employment. Stein:Stemline: Consultancy, Speakers Bureau; Amgen: Consultancy, Speakers Bureau.
Styles APA, Harvard, Vancouver, ISO, etc.
7

Stein, Anthony S., Drew Watson, Prashant Ramachandran Nair, et al. "Superior Therapy Response Predictions for Patients with Myelodysplastic Syndrome (MDS) Using Cellworks Singula™: Mycare-020-02." Blood 136, Supplement 1 (2020): 9–10. http://dx.doi.org/10.1182/blood-2020-142214.

Texte intégral
Résumé :
Background: Therapy selection for MDS patients is often based on information considering only cytogenetics and single molecular aberrations and ignoring other patient-specific omics data that could potentially enable more effective treatments. In turn, despite using cytogenetic and molecular-risk stratification and precision medicine, the current overall outcome of MDS patients remains relatively poor. The Cellworks Singula™ report predicts response for physician prescribed treatments using the novel Cellworks Omics Biology Model (CBM) to simulate downstream molecular effects of cell signaling, drugs, and radiation on patient-specific in silico diseased cells. Methods: The performance of Singula™ was evaluated in an independent, randomly selected, retrospective cohort of 144 MDS patients aged 28 to 89 years (median 69). The pre-defined Singula™ Classifier utilizes an individual's genomics profile to provide a dichotomous prediction of response or non-responses to a given physician prescribed treatment (PPT). Outcome data for these subjects, including measurement of complete response (CR), were obtained from 42 PubMed publications, each including patient genomics data of either karyotyping, targeted gene panels, and/or whole exome sequencing. Blinded to clinical outcomes, Cellworks utilized these data to generate a Singula™ classifier of responder vs non-responder in this MDS cohort. Statistical analyses, including assessments of accuracy, sensitivity, specificity, negative (NPV) and positive predictive (PPV) values were performed on the merged data to compare the Singula™ predicted response with the actual observed CR. Multivariate logistic regression models of complete response were performed incorporating covariates for patient age, PPT, and the Singula™ Classifier. Results: Table 1 reveals that the pre-defined Singula™ classifier had 90.3% (Exact 95% CI: 84.2%, 94.6%) accuracy in predicting observed patient response from the physician prescribed treatment. In this study, Singula™ was able to accurately identify responders with 90.0% (81.2%, 95.6%) sensitivity. Importantly, Singula™ had 90.6% (80.7%, 96.5%) specificity for the subset of 64 patients (44.4%) that had a non-response. For 32% (17/54) of the non-responders patients, Singula™ provided an alternative Standard of Care treatment therapy, as shown in Table 2. The remaining 37 patients were predicted to be non-responders to all remaining Standard of Care options, so did not have alternate treatment predictions. Assuming at least 4% of these non-responding patients would have responded to the alternative Singula™ prescribed therapy, then these data support that Singula™ improves prediction of CR compared to the original PPT (McNemar's p-value < 0.05). In multivariate logistic regression models of CR that included patient age and prescribed drug therapy, the Singula™ Classifier remained an independent, significant predictor of CR (OR > 100, p-value < 0.0001), while both patient age (p = 0.372) and drug therapy (p = 0.720) fell off the model. Conclusions: Cellworks Singula™ has high accuracy and sensitivity in predicting CR for MDS patient response to physician prescribed therapies. Singula™ also has high specificity in identifying patients who are unlikely to respond to physician prescribed therapies and provides alternative treatment recommendations for these patients. The Singula™ Classifier is an independent and superior predictor of CR compared with other clinical (age) or therapeutic (PPT) factors. Figure Disclosures Stein: Amgen: Consultancy, Speakers Bureau; Stemline: Consultancy, Speakers Bureau. Watson:BioAI Health Inc.: Consultancy, Membership on an entity's Board of Directors or advisory committees; Mercy Bioanalytics, Inc.: Consultancy, Membership on an entity's Board of Directors or advisory committees; SEER Biosciences, Inc.: Consultancy, Membership on an entity's Board of Directors or advisory committees; Cellworks Group Inc.: Consultancy, Membership on an entity's Board of Directors or advisory committees; Cellmax Life Inc.: Consultancy, Membership on an entity's Board of Directors or advisory committees. Nair:Cellworks Research India Private Limited: Current Employment. Basu:Cellworks Research India Private Limited: Current Employment. Ullal:Cellworks Research India Private Limited: Current Employment. Ghosh:Cellworks Research India Private Limited: Current Employment. Narvekar:Cellworks Research India Private Limited: Current Employment. Grover:Cellworks Research India Private Limited: Current Employment. Sahu:Cellworks Research India Private Limited: Current Employment. Prakash:Cellworks Research India Private Limited: Current Employment. Behura:Cellworks Research India Private Limited: Current Employment. Balakrishnan:Cellworks Research India Private Limited: Current Employment. Roy:Cellworks Research India Private Limited: Current Employment. Rajagopalan:Cellworks Research India Private Limited: Current Employment. Alam:Cellworks Research India Private Limited: Current Employment. Parashar:Cellworks Research India Private Limited: Current Employment. Mundkur:Cellworks Group Inc.: Current Employment. Christie:Cellworks Group Inc.: Current Employment. Macpherson:Cellworks Group Inc.: Current Employment. Kapoor:Cellworks Research India Private Limited: Current Employment. Marcucci:Abbvie: Speakers Bureau; Novartis: Speakers Bureau; Pfizer: Other: Research Support (Investigation Initiated Clinical Trial); Merck: Other: Research Support (Investigation Initiated Clinical Trial); Takeda: Other: Research Support (Investigation Initiated Clinical Trial); Iaso Bio: Membership on an entity's Board of Directors or advisory committees.
Styles APA, Harvard, Vancouver, ISO, etc.
8

Velcheti, Vamsidhar, Michael Castro, Drew Watson, et al. "Superior overall survival (OS), progression-free survival (PFS), and clinical response (CR) predictions for patients with non-small cell lung cancer (NSCLC) using Cellworks Singula: myCare-022-05." Journal of Clinical Oncology 39, no. 15_suppl (2021): 9117. http://dx.doi.org/10.1200/jco.2021.39.15_suppl.9117.

Texte intégral
Résumé :
9117 Background: The Cellworks Singula Therapeutic Response Index (TRI) has been developed to assist clinicians and NSCLC patients in choosing between competing therapeutic options. In contrast to approaches that consider single aberrations, which often yield limited benefit, Cellworks utilizes an individual patient’s next generation sequencing results and a mechanistic multi-omics biology model, the Cellworks Omics Biology Model (CBM), to biosimulate downstream molecular effects of cell signaling, drugs, and radiation on patient-specific in silico diseased cells. For any individual patient and alternative therapy, Cellworks integrates this biologically modeled multi-omics information into a continuous Singula TRI Score, scaled from 0 (low therapeutic benefit) to 100 (high therapeutic benefit). We demonstrate that Singula is strongly associated with overall survival, progression-free survival and relative therapeutic benefit beyond standard clinical factors, including patient age, gender, and physician prescribed treatments (PPT). Methods: In this study, Singula’s ability to predict response was evaluated in a retrospective cohort of 446 NSCLC patients with OS, PFS, and CR data from The Cancer Genome Atlas (TCGA) project, treated with PPT. As a primary analysis of the CBM and TRI Score, Cox Proportional Hazards (PH) regression and likelihood ratio (LR) tests were used to assess the hypothesis that Singula is predictive of OS, PFS, and CR above and beyond standard clinical factors. A p-value < 0.05 for the corresponding likelihood ratio statistic was required to be considered significant. Results: Multivariate analyses were performed to assess the performance of the Singula Therapy Response Index above and beyond physician’s choice of treatment. The same Singula TRI algorithm and clinical cutoffs were used for all clinical outcome measures. For OS the median survival times for the high and low benefit groups were 60.16 and 28.57 months respectively, based on the median Singula value. Also, the hazard ratio per 25 Singula units for OS was 0.5103 (95% CI: 0.3337 - 0.7804) and the odds ratio for CR was 1.6161. These and further analyses, shown in Table, suggest that Singula TRI provides predictive value of OS, PFS, and CR above and beyond standard clinical factors. Conclusions: The Singula TRI Score provides a continuous measure for alternative NSCLC therapeutic options. In this retrospective cohort, Singula was strongly predictive of OS, PFS, and CR and provided predictive value of OS beyond PPT, patient age and gender. These results will be further validated in prospective clinical studies.[Table: see text]
Styles APA, Harvard, Vancouver, ISO, etc.
9

Wen, Patrick Y., Michael Castro, Drew Watson, et al. "Superior overall survival (OS) and disease-free survival (DFS) predictions for patients with glioblastoma multiforme (GBM) using Cellworks Singula: myCare-022-03." Journal of Clinical Oncology 39, no. 15_suppl (2021): 2017. http://dx.doi.org/10.1200/jco.2021.39.15_suppl.2017.

Texte intégral
Résumé :
2017 Background: The Cellworks Singula Therapeutic Response Index (TRI) has been developed to assist clinicians and GBM patients in choosing between competing therapeutic options. In contrast to approaches that consider single aberrations, which often yield limited benefit, Cellworks utilizes an individual patient’s next generation sequencing results and a mechanistic multi-omics biology model, the Cellworks Omics Biology Model (CBM), to biosimulate downstream molecular effects of cell signaling, drugs, and radiation on patient-specific in silico diseased cells. For any individual patient and alternative therapy, Cellworks integrates this biologically modeled multi-omics information into a continuous Singula TRI Score, scaled from 0 (low therapeutic benefit) to 100 (high therapeutic benefit). We demonstrate that Singula is strongly associated with OS and DFS beyond standard clinical factors, including patient age, patient gender, and physician prescribed treatments (PPT). Methods: In this study, Singula’s ability to predict response was evaluated in a retrospective cohort of 100 GBM patients with OS and DFS data from The Cancer Genome Atlas (TCGA) project, treated with PPT. As a primary analysis of the CBM and TRI Score, Cox Proportional Hazards (PH) regression and likelihood ratio (LR) tests were used to assess the hypothesis that Singula is predictive of OS and DFS above and beyond patient age, patient gender, and PPT. A p-value < 0.05 for the corresponding likelihood ratio statistic was required to be considered significant. Results: Multivariate analyses were performed to assess the performance of the Singula Therapy Response Index after adjusting for the contribution of standard clinical factors. The same Singula TRI algorithm and clinical cutoffs were used for all clinical outcome measures. These analyses, shown in the table, suggests that the proposed Singula TRI provides predictive value of OS and DFS above and beyond patient age, patient gender, and PPT. Conclusions: The Singula TRI Score provides a continuous measure scaled from 0 (low benefit) to 100 (high benefit) for alternative GBM therapeutic options. In this retrospective cohort, Singula was strongly predictive of OS and DFS and provided predictive value beyond PPT, patient age and gender. These results will be further validated in larger scale, prospectively designed clinical studies.[Table: see text]
Styles APA, Harvard, Vancouver, ISO, etc.
10

Goglia, U. "Incretins in healthy and type 2 diabetic people." Journal of AMD 27, no. 2 (2024): 96. http://dx.doi.org/10.36171/jamd24.27.2.3.

Texte intégral
Résumé :
Nell’ultima decade abbiamo osservato sempre maggiormente la diffusione e l’utilizzo di farmaci analoghi recettoriali degli ormoni incretinici nella gestione e nel trattamento di soggetti con diabete mellito tipo 2 ed affetti da obesità. Infatti dalla pubblicazione sul New England Journal of Medicine dello studio Leader nel 2016, che valutava gli effetti cardiovascolari della liraglutide, numerose ulteriori evidenze hanno confermato i benefici clinici degli analoghi recettoriali singoli e doppi di tali ormoni. Ma quale è il ruolo specifico di tali molecole (Glucagon-like Peptide-1 [GLP-1] e Glucose-dependent insulinotropic peptide [ GIP]) nell’uomo? Dopo aver affrontato in un precedente numero di JAMD la storia della scoperta delle incretine, in questa rassegna descriviamo quale sia il principale contributo di tali molecole nei soggetti sani ed il ruolo fisiopatologico nei soggetti affetti da diabete mellito tipo 2, riportando gli esiti delle ricerche che hanno posto le basi per il successivo sviluppo degli analoghi singoli e doppi degli ormoni del sistema incretinico. PAROLE CHIAVE incretine; glucagon-like peptide 1 [GLP-1]; glucose-dependent insulinotropic polypeptide [GIP]; ruolo fisiologico; omeostasi del glucosio.
Styles APA, Harvard, Vancouver, ISO, etc.
11

Sanitaria, Politica. "Collaborazioni Politica sanitaria Prescrivibilità e rimborsabilità degli SGLT2i. La nota 100 AIFA." Cardiologia Ambulatoriale 30, no. 4 (2023): 251–64. http://dx.doi.org/10.17473/1971-6818-2022-4-9.

Texte intégral
Résumé :
Avendo raccolto numerose istanze da parte dei nostri lettori ed avendo effettivamente constatato che alla luce dei recenti risultati di grandi trials clinici e delle modifiche delle Linee Guida internazionali e quindi in ultimo delle disposizioni di AIFA in merito alla prescrivibilità e rimborsabilità della classe di farmaci denominata chimicamente ‘Gliflozine’ e dal punto di vista farmacodinamico ‘SodioGlucosio Transferasi 2 inibitori (SGLT2i), abbiamo voluto riportare quali siano le regole prescrittive attuali in Italia. Potrebbero esserci modifiche a breve per il riconoscimento di alcune indicazioni a singole molecole. Si precisa che al momento in Italia sono in commercio 4 molecole appartenenti a questa classe di farmaci.
Styles APA, Harvard, Vancouver, ISO, etc.
12

Cuesta, Virginia, Maida Vartanian, Pilar de la Cruz, Ganesh D. Sharma, and Fernando Langa. "The Influence of the Central Metal Ion on the Electronic and Photovoltaic Properties of Metalloporphyrins [M= Zn(II), Ni(II), Cu(II), Au(III)] Systems." ECS Meeting Abstracts MA2023-01, no. 15 (2023): 1395. http://dx.doi.org/10.1149/ma2023-01151395mtgabs.

Texte intégral
Résumé :
Although the pioneering use of porphyrins in organic solar cells (OSCs) was disappointing as reported efficiencies were very low, the situation has changed over the last five years as Zn-porphyrins with ABAB structures linked to acceptor units through triple bonds have been applied as donors resulting in efficiencies of up to 12% in binary OSCs and more than 15% in ternary OSCs. The optical and electrochemical properties of porphyrins can be adjusted by molecular design and functionalization on the b or meso positions of the porphyrin ring as well as by introduction of different central metal ions. The choice of the centrally bounded metal cation within the porphyrin core plays an important role in the electronic properties allowing the modulation of the frontier orbital levels and thereby use the porphyrin-based molecule as donor or acceptor component of the device. Due to the high HOMO level of Zn-Porphyrin derivatives, the Voc of OSCs using this family of compounds are lower than 0.9 V limiting the PCE of devices. We have described that Ni-porphyrins derivatives allow the design of OSCs with voltage higher than 1V. These systems present slightly higher optical bandgaps but the deeper highest occupied molecular orbital (HOMO) energy level make available to reach good PCE values of the solar devices. While porphyrins and their derivatives have been extensively used as donor component in the BHJ active layer of OSCs, the investigation of porphyrin-based materials as electron acceptor is very limited. Recently, we designed a new A2-D-A1-D-A2 non fullerene small molecule acceptor (NFSMA) with broad absorption up to 920 nm and a great absorption coefficient where A1 core is Au(III) porphyrin. This molecule, when used in OSC with a polymer donor yielded a PCE=9.24%. Nevertheless, the use of other central metals such as Cu(II) in the porphyrin core has been scarcely used in OSCs, the studied devices presented low efficiencies (≤ 3%). These outcomes demonstrated that metalloporphyrins, which is different from Zn-porphyrins, also have great potential for the design of NFSMAs for efficient OSCs. Also, we have studied A-π-D-π-A small molecules based on Cu(II) Porphyrin, scarcely used in OSCs, presenting an ambipolar behaviour, as donor and as acceptor. Here, I´ll present our recent work in design, synthesis, and application of porphyrin-based small molecules with different central metal for highly efficient OSCs. References V. Cuesta, M. Vartanian, P. de la Cruz, R. Singhal, G. D. Sharma and F. Langa. J. Mater. Chem. A, 2017, 5, 1057. S. Arrechea, A. Aljarilla, P. de la Cruz, M. K. Singh, G. D. Sharma and F. Langa. J. Mater. Chem. C, 2017, 5, 4742. M. Vartanian, R. Singhal, P. de la Cruz, S. Biswas, G. D. Sharma and F. Langa. ACS Appl. Energy, Mater., 2018, 1, 1304. M. Vartanian, P. de la Cruz, F. Langa, S. Biswas and G. D. Sharma. Nanoscale, 2018, 10, 12100. M. Vartanian, R. Singhal, P. de la Cruz, G. D. Sharma and F. Langa. Chem. Commun., 2018, 54, 14144. V. Cuesta, R. Singhal, P. de la Cruz, G. D. Sharma and F. Langa. ACS Appl. Mater. Interfaces, 2019, 11, 7216. Cuesta, R. Singhal, P. de la Cruz, G. D. Sharma and F. Langa, ChemSusChem, 2021, 14, 3439. H. Dahiya, V. Cuesta, P. de la Cruz, F. Langa and G. D. Sharma ACS Appl. Energy Mater., 2021, 4, 4498. Figure 1
Styles APA, Harvard, Vancouver, ISO, etc.
13

Su Yuting, 苏玉婷, та 盖宏伟 Gai Hongwei. "单分子计数免疫分析". Laser & Optoelectronics Progress 59, № 6 (2022): 0617011. http://dx.doi.org/10.3788/lop202259.0617011.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
14

Cuesta, Virginia, Maida Vartanian, Pilar de la Cruz, Ganesh D. Sharma, and Fernando Langa. "Molecular Engineering of Low-Bandgap Porphyrins for Highly Efficient Organic Solarcells." ECS Meeting Abstracts MA2022-01, no. 14 (2022): 981. http://dx.doi.org/10.1149/ma2022-0114981mtgabs.

Texte intégral
Résumé :
Organic solar cells (OSCs) based on solution-processed bulk heterojunction (BHJ) active layers have emerged as promising solutions for the conversion of solar energy into electrical energy in building and indoor applications due to their unique advantages, such as being lightweight and semitrans-parent and the possibility of being processed by low-cost roll-to-roll methods. The BHJ active layer employed for OSCs consists of a blend of an electron-donating material and an electron-accepting material creating internal donor-acceptor heterojunctions, and their optical and electrochemical properties are very important for the realization of a high-power conversion efficiency (PCE). The optical and electrochemical properties of porphyrins can be adjusted by molecular design and functionalization on the b or meso positions of the porphyrin ring as well as by introduction of different central metal ions. Although the pioneering use of porphyrins in OSCs was disappointing, as reported efficiencies were very low;the situation has changed over the last five years as Zn-porphyrins with ABAB structures linked to acceptor units, having relatively long-lived singlet excited states, have been successfully used as donors or acceptors, resulting in increased efficiencies. Here, I´ll present our recent work in design, synthesis, and application of porphyrin-based small molecules for highly efficient OSCs with VOC>1V and PCE>15%. References V. Cuesta, M. Vartanian, P. de la Cruz, R. Singhal, G. D. Sharma and F. Langa, J. Mater. Chem. A,2017, 5, 1057. S. Arrechea, A. Aljarilla, P. de la Cruz, M. K. Singh, G. D. Sharma, F. Langa. J. Mater. Chem. C, 2017, 5, 4742. M. Vartanian, R. Singhal, P. de la Cruz, S. Biswas, G. D. Sharma and F. Langa, ACS Appl. Energy Mater. 2018, 1, 1304. M. Vartanian, P. de la Cruz, F. Langa, S. Biswas, G. D. Sharma. Nanoscale, 2018, 10, 12100. M. Vartanian, R. Singhal, P. de la Cruz, G. D. Sharma, F. Langa, Chem. Commun, 2018, 54, 14144. V. Cuesta, R. Singhal, P. de la Cruz, G. D. Sharma, F. Langa, ACS Appl. Mater. Interfaces, 2019, 11, 7216 . Cuesta, R. Singhal, P. de la Cruz, G. D. Sharma, F. Langa, ChemSusChem 2021, 14, 3439. H. Dahiya, V. Cuesta, P. de la Cruz, F. Langa, G. D. Sharma ACS Appl. Energy Mater. 2021, 4, 4498.
Styles APA, Harvard, Vancouver, ISO, etc.
15

Yanagida, Toshio. "S2h1-2 Single molecule study for elucidating the mechanism involved in utilizing fluctuations by biosystems(S2-h1: "Single Molecule Analysis of Molecular Motor",Symposia,Abstract,Meeting Program of EABS & BSJ 2006)." Seibutsu Butsuri 46, supplement2 (2006): S127. http://dx.doi.org/10.2142/biophys.46.s127_1.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
16

Hayashi, Fumio. "1P540 Single-molecular behavior of rhodopsin in native disc membrane(26. Single molecule biophysics,Poster Session,Abstract,Meeting Program of EABS & BSJ 2006)." Seibutsu Butsuri 46, supplement2 (2006): S281. http://dx.doi.org/10.2142/biophys.46.s281_4.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
17

Ishii, Takaaki, Atsuto Katano, Yoshihiro Murayama, and Masaki Sano. "1P560 Observing mechanical unfolding and folding process of single molecular protein by AFM(26. Single molecule biophysics,Poster Session,Abstract,Meeting Program of EABS & BSJ 2006)." Seibutsu Butsuri 46, supplement2 (2006): S286. http://dx.doi.org/10.2142/biophys.46.s286_4.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
18

Torisawa, Takayuki, Muneyoshi Ichikawa, Takuya Kobayashi, Takashi Murayama, and Yoko Toyoshima. "3P157 DIFFUSIVE MOVEMENT OF A SINGLE-MOLECULE MAMMALIAN CYTOPLASMIC DYNEIN(Molecular motor,The 48th Annual Meeting of the Biophysical Society of Japan)." Seibutsu Butsuri 50, supplement2 (2010): S172. http://dx.doi.org/10.2142/biophys.50.s172_4.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
19

LI, Chun-Biu, and Tamiki KOMATSUZAKI. "Handling Noisy Data from Single Molecule Experiments." Seibutsu Butsuri 54, no. 5 (2014): 257–58. http://dx.doi.org/10.2142/biophys.54.257.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
20

Luo Tingdan, 罗婷丹, та 李依明 Li Yiming. "深度学习在单分子定位显微镜中的应用". Chinese Journal of Lasers 49, № 24 (2022): 2407206. http://dx.doi.org/10.3788/cjl202249.2407206.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
21

Iwasaki, Satoshi, Ken'ya Furuta, Toshihiko Sakuma, Masaki Edamatsu, and Yoko Y. Toyoshima. "2P227 Analysis of single molecule motility of mitotic kinesins(37. Molecular motor (II),Poster Session,Abstract,Meeting Program of EABS & BSJ 2006)." Seibutsu Butsuri 46, supplement2 (2006): S352. http://dx.doi.org/10.2142/biophys.46.s352_3.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
22

Ritchie, Ken. "S01H3 Single molecule imaging of diffusion in E. Coll membranes(Systems Biology of Intracellular Signaling as Studied by Single-Molecule Imaging)." Seibutsu Butsuri 47, supplement (2007): S1. http://dx.doi.org/10.2142/biophys.47.s1_3.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
23

Noji, Hroyuki. "SINGLE MOLECULE BIOPHYSICS OF F_1-ATPase motor protein." Proceedings of the Asian Pacific Conference on Biomechanics : emerging science and technology in biomechanics 2007.3 (2007): S1. http://dx.doi.org/10.1299/jsmeapbio.2007.3.s1.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
24

ZHAO Yuehan, 赵悦晗, та 郝翔 HAO Xiang. "多色单分子定位显微技术研究进展（特邀）". ACTA PHOTONICA SINICA 51, № 8 (2022): 0851517. http://dx.doi.org/10.3788/gzxb20225108.0851517.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
25

Wang Siyuan, 王思媛, 刘虹遥 Liu Hongyao, 路鑫超 Lu Xinchao та 黄成军 Huang Chengjun. "等离激元纳米孔用于单分子光学检测的研究进展". Chinese Journal of Lasers 50, № 1 (2023): 0113012. http://dx.doi.org/10.3788/cjl220914.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
26

Liu Yizhe, 刘一哲, 赵唯淞 Zhao Weisong, 刘宇桢 Liu Yuzhen та 李浩宇 Li Haoyu. "自适应混合发射单分子定位算法". Chinese Journal of Lasers 50, № 21 (2023): 2107106. http://dx.doi.org/10.3788/cjl230653.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
27

Cao, Jianshu. "1S5-5 Generic models for single molecule biological processes : Generic models for single molecule biological processes(1S5 Linking single molecule spectroscopy and energy landscape perspectives,The 46th Annual Meeting of the Biophysical Society of Japan)." Seibutsu Butsuri 48, supplement (2008): S5. http://dx.doi.org/10.2142/biophys.48.s5_1.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
28

Ishiwata, Shin'ichi. "S2h1-4 Hierarchical Construction of Biological Motility System(S2-h1: "Single Molecule Analysis of Molecular Motor",Symposia,Abstract,Meeting Program of EABS & BSJ 2006)." Seibutsu Butsuri 46, supplement2 (2006): S127. http://dx.doi.org/10.2142/biophys.46.s127_3.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
29

Fernandez, Julio M. "S3B1 Protein mechanics studied with single molecule AFM techniques.(Single Molecure Dynamics and Reactions)." Seibutsu Butsuri 42, supplement2 (2002): S13. http://dx.doi.org/10.2142/biophys.42.s13_4.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
30

P, Srivastava. "Comparative Modeling and Molecular Interaction Study for the Management of AMD and CRVO Ocular Disorder." Open Access Journal of Ophthalmology 8, no. 1 (2023): 1–13. http://dx.doi.org/10.23880/oajo-16000263.

Texte intégral
Résumé :
Age Related Macular Degeneration (AMD) and Central Retinal Vein Occlusion (CRVO) are the rare and leading cause of blindness among patients with ocular problem. Many proteins are reported in the progression of these ocular disorders. Proteins which are directly involved in the development of this disorder reported in the literature, their sequence related information retrieved from biological databases. In silico technique was implemented in order to characterize the properties and structures of the proteins using ProtParam. For studying about the potential phosphorylation sites in protein generally NetPhos server was used whereas for denoting the location of signal peptide cleavage sites and their presence the server which is used is SingalP server. For prediction of secondary structure prediction of proteins is done by using SOPMA. The SOSUI server performs the identification of trans-membrane regions. The 3D dimensional structure was modeled using Swiss Model Workspace and Modeller. Ramachandran plot was used to validate the stereochemical properties of the predicted structures because it is a very important step after 3D structure prediction. Docking of screened phytochemicals with selected proteins was performed by AutoDock. Docking study revealed that Curcumin (binding energy: -8.35) and Berberine (binding energy: -7.14) can be used as better therapeutic lead molecule for the cure of CRVO and AMD respectively.
Styles APA, Harvard, Vancouver, ISO, etc.
31

Sei, Kazuto, Akinori Baba, Chun Biu Li, and Tamiki Komatsuzaki. "1P537 Randomness and Memory in Single Molecule Time Series(26. Single molecule biophysics,Poster Session,Abstract,Meeting Program of EABS & BSJ 2006)." Seibutsu Butsuri 46, supplement2 (2006): S281. http://dx.doi.org/10.2142/biophys.46.s281_1.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
32

Yang Jianyu, 杨建宇, 董浩 Dong Hao, 邢福临 Xing Fulin, 胡芬 Hu Fen, 潘雷霆 Pan Leiting та 许京军 Xu Jingjun. "单分子定位超分辨成像技术进展及应用". Laser & Optoelectronics Progress 58, № 12 (2021): 1200001. http://dx.doi.org/10.3788/lop202158.1200001.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
33

Lin Zhaojun, 林昭珺, 常桓梽 Chang Huanzhi та 李依明 Li Yiming. "高通量单分子定位显微成像技术进展（特邀）". Laser & Optoelectronics Progress 61, № 6 (2024): 0618004. http://dx.doi.org/10.3788/lop232570.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
34

Qiao Yuyuan, 乔钰媛, 张亦晴 Zhang Yiqing, 陈太龙 Chen Tailong, 曹健 Cao Jian, 刘建丽 Liu Jianli та 徐帆 Xu Fan. "单分子定位超分辨显微技术在神经生物学中的应用（特邀）". Chinese Journal of Lasers 52, № 9 (2025): 0907301. https://doi.org/10.3788/cjl241349.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
35

Kinosita, Kazuhiko. "S2h1-1 Probing motor dynamics with huge and small tags(S2-h1: "Single Molecule Analysis of Molecular Motor",Symposia,Abstract,Meeting Program of EABS & BSJ 2006)." Seibutsu Butsuri 46, supplement2 (2006): S126. http://dx.doi.org/10.2142/biophys.46.s126_4.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
36

Hirokawa, Nobutaka. "S2h1-3 Mechanism of Motility of Monomeric Motor, KIF 1A(S2-h1: "Single Molecule Analysis of Molecular Motor",Symposia,Abstract,Meeting Program of EABS & BSJ 2006)." Seibutsu Butsuri 46, supplement2 (2006): S127. http://dx.doi.org/10.2142/biophys.46.s127_2.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
37

Takeda, Mizuho, Hiromi Imamura, Katsuya Shimabukuro, Chiyo Ikeda, Masasuke Yoshida, and Ken Yokoyama. "1P533 Mechanism of Inhibition of the V-type Molecular Motor by Tributyltin Chloride(26. Single molecule biophysics,Poster Session,Abstract,Meeting Program of EABS & BSJ 2006)." Seibutsu Butsuri 46, supplement2 (2006): S280. http://dx.doi.org/10.2142/biophys.46.s280_1.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
38

Gopich, Irina V. "1S5-4 Decoding the pattern of photon colors in single-molecule FRET : Decoding the pattern of photon colors in single-molecule FRET(1S5 Linking single molecule spectroscopy and energy landscape perspectives,The 46th Annual Meeting of the Biophysical Society of Japan)." Seibutsu Butsuri 48, supplement (2008): S4—S5. http://dx.doi.org/10.2142/biophys.48.s4_6.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
39

Fujisawa, Ryo, Daichi Okuno, and Hiroyuki Noji. "1P526 Single-molecule analysis of F_1-motor loaded with nonhydrolyzable substrate(26. Single molecule biophysics,Poster Session,Abstract,Meeting Program of EABS & BSJ 2006)." Seibutsu Butsuri 46, supplement2 (2006): S278. http://dx.doi.org/10.2142/biophys.46.s278_2.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
40

Ueno, Taro, Takashi Tanii, Naonobu Shimamoto, et al. "1P542 Single molecule imaging of chaperonin functions using zero-mode waveguides(26. Single molecule biophysics,Poster Session,Abstract,Meeting Program of EABS & BSJ 2006)." Seibutsu Butsuri 46, supplement2 (2006): S282. http://dx.doi.org/10.2142/biophys.46.s282_2.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
41

Otsuka, Shotaro, Hirohide Takahashi, and Shige H. Yoshimura. "1P543 Single-molecule structural and functional analyses of nuclear pore complex(26. Single molecule biophysics,Poster Session,Abstract,Meeting Program of EABS & BSJ 2006)." Seibutsu Butsuri 46, supplement2 (2006): S282. http://dx.doi.org/10.2142/biophys.46.s282_3.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
42

Morimatsu, Miki, Hiroaki Takagi, Kosuke Ohta, Toshio Yanagida, and Yasushi Sako. "1P547 Kinetic analysis of EGFR/Grb2 interactions using single-molecule imaging(26. Single molecule biophysics,Poster Session,Abstract,Meeting Program of EABS & BSJ 2006)." Seibutsu Butsuri 46, supplement2 (2006): S283. http://dx.doi.org/10.2142/biophys.46.s283_3.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
43

Nguyen, Anh Thi Van, Y. Kamio, and H. Higuchi. "1H1430 Single-Molecule Visualization of Hemolysin Assembly on Erythrocyte Membranes." Seibutsu Butsuri 42, supplement2 (2002): S44. http://dx.doi.org/10.2142/biophys.42.s44_3.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
44

Wu Jie, 武杰, 黄嘉玲 Huang Jialing, 王越 Wang Yue, 李政昊 Li Zhenghao, 周文超 Zhou Wenchao та 吴一辉 Wu Yihui. "基于单分子检测原理的MicroRNA超灵敏检测研究". Acta Optica Sinica 43, № 13 (2023): 1317001. http://dx.doi.org/10.3788/aos230453.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
45

Ueno, Hiroshi, Kazuhito Tabata, Toshiharu Suzuki, Toru Ide, Masasuke Yoshida, and Hiroyuki Noji. "1P528 Development of the Single Molecule Imaging System of the F_0 Motor(26. Single molecule biophysics,Poster Session,Abstract,Meeting Program of EABS & BSJ 2006)." Seibutsu Butsuri 46, supplement2 (2006): S278. http://dx.doi.org/10.2142/biophys.46.s278_4.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
46

Thumkeo, Dean, Takuji Yoshihara, Toshio Yanagida, and Masahiro Ueda. "1P538 Single-molecule imaging of Ras-PI3K signaling in chemotaxing Dictyostelium cells(26. Single molecule biophysics,Poster Session,Abstract,Meeting Program of EABS & BSJ 2006)." Seibutsu Butsuri 46, supplement2 (2006): S281. http://dx.doi.org/10.2142/biophys.46.s281_2.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
47

Baba, Akinori, and Tamiki Komatsuzaki. "1P539 Applicability of local ergodic state analysis of single molecule time series(26. Single molecule biophysics,Poster Session,Abstract,Meeting Program of EABS & BSJ 2006)." Seibutsu Butsuri 46, supplement2 (2006): S281. http://dx.doi.org/10.2142/biophys.46.s281_3.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
48

Yokota, Hiroaki, Yong-Woon Han, Jean-Francois Allemand, et al. "1P556 Novel microscopy for simultaneous single molecule measurement of DNA/protein interaction(26. Single molecule biophysics,Poster Session,Abstract,Meeting Program of EABS & BSJ 2006)." Seibutsu Butsuri 46, supplement2 (2006): S285. http://dx.doi.org/10.2142/biophys.46.s285_4.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
49

Taniguchi, Masateru. "1SBP-04 Single Molecule Electrical Sequencing of DNA and microRNA(1SBP Advanced Single Molecule Sequencing System,Symposium,The 51th Annual Meeting of the Biophysical Society of Japan)." Seibutsu Butsuri 53, supplement1-2 (2013): S87. http://dx.doi.org/10.2142/biophys.53.s87_5.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
50

Nakamura, Mariko, Hiroshi Ueno, Hiromi Imamura, and Hiroyuki Noji. "1P525 Designing a mutant F_1-ATPase for easy and rapid single molecule analysis(26. Single molecule biophysics,Poster Session,Abstract,Meeting Program of EABS & BSJ 2006)." Seibutsu Butsuri 46, supplement2 (2006): S278. http://dx.doi.org/10.2142/biophys.46.s278_1.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
Vous pouvez également être intéressé par les bibliographies sur le sujet « Singola molecola » pour d’autres types de sources :
Thèses Livres
Nous offrons des réductions sur tous les plans premium pour les auteurs dont les œuvres sont incluses dans des sélections littéraires thématiques. Contactez-nous pour obtenir un code promo unique!

Vers la bibliographie